Retraction: Water-Free Topical Cyclosporine Improved Dryness Score in Dry Eye

The complete response letter (CRL) specifies that the current dosage duration of aflibercept is still safe but extending the duration is not approved.

Excessive use of digital devices and mental health issues can both contribute to the development of dry eye syndrome.

The topical ocular drug is an investigational new drug candidate that requires more well-controlled studies to establish efficacy, according to the FDA.

Both refractive and corneal astigmatism saw an increase in prevalence in children after the COVID-19 pandemic, with corneal changes potentially playing a part.

The topical treatment had no significant effect on total or central corneal fluorescence staining score.

Clinical trials for diabetic macular edema (DME) continue to see disparities in enrollment.